[Surviving resistance to hormone therapy in hormone-dependent metastatic breast carcinoma].
Onkologicka klinika VFN v Praze, Praha. petra.tesarova@vfn.cz
P
P
Tesarova
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D000068338:Everolimus; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D000068338:Everolimus; D020123:Sirolimus